Historically, mpox was confined to a few African countries, with mortality rates varying significantly due to differences in healthcare quality between regions.

Dr. Mbala-Kingebeni suggested that strategies used to control Ebola outbreaks, such as targeted vaccinations around identified cases, could be effectively applied to manage mpox, especially given the anticipated short supply of vaccines.

The World Health Organization recently declared a public health emergency regarding the rise in mpox cases, particularly in the Democratic Republic of the Congo (DRC), where a new strain has raised concerns of a potential pandemic.

In response to the escalating situation, the European Union and Bavarian Nordic have pledged 215,000 mpox vaccines to the DRC, with the United States also contributing 50,000 doses.

While vaccines are available to help curb the outbreak, their accessibility remains a significant issue in poorer countries, contrasting with the successful vaccination and contact tracing efforts seen in wealthier nations.

Health authorities are closely monitoring the situation as the number of mpox cases increases, which could significantly impact public health policies.

In addition to mpox, a new study published in JAMA has revealed that children with long COVID-19 exhibit varying symptoms based on their age, highlighting the need for tailored healthcare responses.

CDC Director Jean Kaseya highlighted that ongoing armed conflict in Eastern Congo complicates disease control efforts, particularly in South Kivu province, where mass internal displacement is occurring.

Funding initiatives are being implemented to support awareness-raising activities and enhance cross-border coordination to effectively monitor and reduce the spread of mpox.

Dr. Samuel Boland from the WHO emphasized the importance of utilizing radio communications to reach inaccessible populations during the mpox outbreak.

Dr. Hunter noted that the quality of medical care available can heavily influence mortality rates, with better healthcare likely leading to lower mortality in developed countries.

The CDC and FDA are advocating for annual vaccinations against COVID, influenza, and RSV to streamline healthcare visits and improve overall public health.